Showing only trials that are Phase 1

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Testing a new treatment to understand it’s efficacy and the best dose for patients

Expected to end: 31/03/2028

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

The first trial in humans for a new type of BTK degrader

Expected to end: 01/01/2028

Study to Evualate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants with B-Cell Malignancies

Assessing the safety and effectiveness of a medication called ABBV-101 in people with certain types of relapsed non-Hodgkin’s lymphomas

Expected to end: 01/03/2031

A study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

An early phase study of the efficacy and safety of a new drug

Expected to end: 08/01/2026

Study to Evaluate CCS1477 in Haematological Malignancies

Finding out more about a new type of targeted treatment

Expected to end: 30/06/2025

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Understanding the best dosage for a BTK inhibitor called Pirtobrutinib

Expected to end: 01/01/2028

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

A first-in-human study to test the safety and efficacy of a new targeted treatment

Expected to end: 31/05/2025

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Understanding the dosage and safety of a new type of treatment

Expected to end: 30/08/2027

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies (ELM-1)

Understanding the best doses for Odronextamb in patients with a type of protein on their B-cells

Expected to end: 30/09/2025